Surgery Partners, Inc. (NASDAQ:SGRY) Receives $37.38 Average Price Target from Analysts

Shares of Surgery Partners, Inc. (NASDAQ:SGRY) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $36.56.

Several research analysts have weighed in on SGRY shares. Royal Bank of Canada lowered their price objective on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 20th. Benchmark reaffirmed a “buy” rating and set a $50.00 price target on shares of Surgery Partners in a research report on Monday, August 26th. Macquarie reissued an “outperform” rating and issued a $34.00 price objective on shares of Surgery Partners in a report on Tuesday, November 19th. Bank of America started coverage on shares of Surgery Partners in a report on Monday, December 16th. They set a “buy” rating and a $30.00 target price on the stock. Finally, KeyCorp assumed coverage on Surgery Partners in a research note on Friday, October 11th. They issued a “sector weight” rating for the company.

Surgery Partners Stock Up 8.2 %

Shares of SGRY opened at $21.22 on Friday. The firm has a market cap of $2.70 billion, a P/E ratio of -44.21, a price-to-earnings-growth ratio of 17.40 and a beta of 2.58. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.66 and a current ratio of 1.80. Surgery Partners has a 52 week low of $19.50 and a 52 week high of $35.29. The firm’s 50-day simple moving average is $25.99 and its 200 day simple moving average is $27.74.

Surgery Partners (NASDAQ:SGRY) last posted its earnings results on Tuesday, November 12th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.06). The firm had revenue of $770.40 million during the quarter, compared to analyst estimates of $768.99 million. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. Surgery Partners’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.15 EPS. On average, analysts forecast that Surgery Partners will post 0.71 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. KBC Group NV boosted its holdings in shares of Surgery Partners by 31.8% in the 3rd quarter. KBC Group NV now owns 2,385 shares of the company’s stock valued at $77,000 after purchasing an additional 576 shares in the last quarter. Quarry LP lifted its position in shares of Surgery Partners by 133.1% during the 2nd quarter. Quarry LP now owns 3,082 shares of the company’s stock worth $73,000 after buying an additional 1,760 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in Surgery Partners by 747.6% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,831 shares of the company’s stock valued at $124,000 after buying an additional 3,379 shares in the last quarter. Creative Planning bought a new position in Surgery Partners in the third quarter valued at about $258,000. Finally, Versor Investments LP bought a new position in Surgery Partners in the third quarter valued at about $271,000.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.